Product Description
ION455, also known as AZD7503, is an investigational antisense medicine designed for the treatment of nonalcoholic steatohepatitis (NASH). (Sourced from: https://www.ionispharma.com/ionis-innovation/pipeline/)
Mechanisms of Action: HSD17B13 Inhibitor
Novel Mechanism: Yes
Modality: Nucleic Acid
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Japan, United States
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Fatty Liver, Alcoholic|Hepatitis, Alcoholic|Liver Diseases, Alcoholic|Non-alcoholic Steatohepatitis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| jRCT2071230075 | P1 |
Recruiting |
Fatty Liver, Alcoholic |
2024-12-31 |
|||
| D9230C00003 | P1 |
Completed |
Fatty Liver, Alcoholic|Non-alcoholic Steatohepatitis|Liver Diseases, Alcoholic|Hepatitis, Alcoholic |
2024-02-27 |
50% |
2024-03-20 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
11/23/2020 |
News Article |
Ionis announces third investigational antisense medicine to treat nonalcoholic steatohepatitis (NASH) enters development |